Therapy Areas: Devices
LIDDS AB awarded European patent
5 June 2018 -

LIDDS AB (Nasdaq First North: LIDDS) has been granted a European patent related to devices and methods of injection, the Swedish pharmaceutical company announced on Tuesday.

The patent approved by the European Patent Office describes devices and methods for the reconstitution and administration of Liproca Depot and other NanoZolid formulations, involving the dispersion of nanoparticles to injectable suspensions for administration as local drug delivery depots.

Following this decision, the patent is now approved in all major markets, including North America, Asia and Europe. It provides protection for all drug formulations based on the NanoZolid technology.

The European patent application was submitted by LIDDS with application number EP09815647 and the title "Injector Device".

LIDDS develops medications for cancer and other diseases with its patented NanoZolid technology, which releases the medication locally and allows for controlled, long-term and adjusted release of the medication for up to six months.

Prostate cancer product Liproca Depot is the company's most advanced project and is currently in Phase IIb.

Login
Username:

Password: